Click above to get an executive summary of a new report we’re launching on how digital therapeutics developers can satisfy diverse stakeholder needs. We’ll automatically email you a copy of the full report once available.
The digital therapeutics (DTx) market, conservatively defined, is currently expanding at 64% CAGR and could be worth nearly half a billion U.S. dollars by 2021. But, to reach its full potential, Syneos Health believes DTx developers must learn from the setbacks encountered by both life sciences and technology companies in recent years—especially in areas of consumer trust.
If you had the chance to attend our Digital Medicine and MedTech Showcase panel, "Pioneers and New Frontiers: Technologies Positioned to Change the Future and Blazing a Trail Toward Commercialization," you heard from pioneering companies and alliances in the DTx space regarding unique set of challenges posed by this new class of treatments and the new roadmap needed for commercial success.
